![]() |
市场调查报告书
商品编码
1423668
2030 年体外心律调节器市场预测:按设备、应用、最终用户和地区进行的全球分析External Pacemaker Market Forecasts to 2030 - Global Analysis By Device (Single Chamber and Dual Chamber), By Application (Acute Myocardial Infarction, Bradycardia, Heart Block and Other Applications), End User and By Geography |
根据 Stratistics MRC 的数据,2023 年全球体外心律调节器市场规模为 17.6 亿美元,预测期内复合年增长率为 5.4%,到 2030 年将达到 25.4 亿美元。
体外心律调节器是医疗设备,旨在透过向外部传递电脉衝来调节心律。它由连接到外部发生器的电极组成,该发生器发出受控的电信号。该设备被放置在患者的胸部,并向心臟发送电脉衝,以解决异常心律,例如心搏过缓其他传导异常,直到实施永久解决方案。
根据美国疾病管制与预防中心 (CDC) 的数据,大约每 40 秒就有一名美国心臟病发作。每年有 805,000 名美国人心臟病发作,其中 605,000 人是首次心臟病发作。
老年人口不断增加
老年人通常会出现心率异常,例如心搏过缓或心臟传导阻滞。随着人口老化的扩大,需要起搏器介入的心臟病盛行率也在增加。在这些情况下,外部起搏器可作为临时解决方案,在患者等待永久植入时提供即时心臟支持,或作为心臟手术后的临时措施。此外,世界人口老化与起搏器需求增加直接相关,从而推动市场成长。
心律调节器高成本
儘管这些设备对于心臟管理至关重要,但它们的采购和维护成本都很高。先进的技术、材料和製造流程导致价格急剧上升。此外,某些地区的医疗保健预算限制和有限的保险覆盖范围造成了经济障碍,阻碍患者获得救生设备。
新兴国家可支配所得增加
收入水准的提高使新兴国家有可能购买先进的医疗保健服务和医疗设备,包括心律调节器。这增加了对心臟治疗的需求并增加了获得昂贵医疗技术的机会。负担能力的提高鼓励更多的人选择起搏器植入和治疗,从而推动市场成长。此外,医疗保健支出的增加和保险覆盖范围的扩大也有助于提高这些经济体的普及并改善市场形势。
与替代疗法的竞争
药物治疗、改变生活方式和其他非侵入性心臟治疗等替代疗法是起搏器植入的治疗方法疗法。对于某些心臟疾病,出于对手术、设备依赖性和成本的担忧,患者可能会在考虑起搏器之前选择替代疗法。此外,非侵入性手术的进步和替代疗法的研究可能会提供可行的选择,并立即减少对起搏器的需求。
COVID-19 大流行对体外心律调节器市场产生了重大影响。医疗服务、选择性手术和医院就诊的中断导致非紧急治疗的推迟,包括起搏器植入。供应链中断和与流行病相关的医疗保健资源的优先顺序影响了设备的可得性。患者不愿就医和住院也导致心律调节器手术减少,导致市场成长暂时下降。
预计在预测期内医院部门将是最大的
在预测期内,医院部门预计将是最大的。该医院是心臟护理的主要中心,拥有专业的基础设施和熟练的医疗专业人员,能够诊断和治疗需要外部起搏器的复杂心臟病。此外,由于需要即时进行心臟治疗的患者大量涌入,这些设施是起搏器植入和管理的主要中心。该医院的综合医疗服务和专业心臟科巩固了其作为体外起搏器市场最大贡献者的地位。
预计心臟块领域在预测期内复合年增长率最高
预计心臟传导阻滞细分市场在预测期内将出现良好的成长率。这是由于心臟传导阻滞的盛行率不断增加,即心臟的电讯号被延迟或阻塞。在这种情况下,外部心律调节器是调节心律的重要临时解决方案,有助于满足不断增长的需求。此外,技术进步和人们对心臟健康意识的提高预计将推动采用外部起搏器进行心臟传导阻滞管理,从而刺激该领域的快速成长。
由于其先进的医疗基础设施、心臟病的高盛行率和高昂的医疗费用,北美预计将在体外起搏器市场中占据最大的市场占有率。此外,主要市场参与者的存在和广泛的研发活动也有助于形成市场主导地位。此外,不断增加的心臟治疗技术进步倡议以及积极采用创新医疗解决方案的倡议正在加强北美在体外起搏器市场的主导地位。
由于心臟病患病率上升和老年人口不断增加,预计亚太地区外部起搏器市场将显着增长。此外,医疗基础设施的改善、先进医疗保健意识的提高以及可支配收入的增加正在推动体外起搏器的采用率。此外,与国际医疗设备製造商的合作伙伴关係以及政府的支持措施进一步推动了市场扩张,显示亚太地区体外起搏器市场的成长前景显着。
According to Stratistics MRC, the Global External Pacemaker Market is accounted for $1.76 billion in 2023 and is expected to reach $2.54 billion by 2030 growing at a CAGR of 5.4% during the forecast period. An external pacemaker is a medical device designed to regulate heart rhythm by delivering electrical impulses externally. It consists of electrodes connected to an external generator that emits controlled electrical signals. This device is placed on the patient's chest and transmits electrical pulses to the heart, addressing abnormal heart rhythms like bradycardia or other conduction abnormalities until a permanent solution is implemented.
According to the Centers for Disease Control and Prevention (CDC), approximately every 40 seconds an American will have a heart attack. Every year, 805,000 Americans have a heart attack, 605,000 of them for the first time.
Growing geriatric population
Elderly individuals commonly experience heart rhythm abnormalities like bradycardia or heart block. As the ageing demographic expands, there's a higher prevalence of cardiac conditions necessitating pacemaker intervention. External pacemakers serve as temporary solutions in these cases, providing immediate cardiac support while patients await permanent implantation or temporary measure post-cardiac procedures. Additionally, the rising ageing population worldwide directly correlates with an increased demand for external pacemakers, fostering market growth.
High cost of pacemakers
These devices are crucial for cardiac management, but they involve substantial expenses for both procurement and maintenance. The sophisticated technology, materials, and manufacturing processes contribute to elevated prices. Additionally, healthcare budget constraints and limited insurance coverage in certain regions create financial barriers, hindering patient access to these life-saving devices, which limits their accessibility to a broader population.
Increasing disposable income in emerging economies
Due to the rise in income levels, emerging economies can afford advanced healthcare services and devices, including pacemakers. This leads to a higher demand for cardiac care and better access to expensive medical technologies. Improved affordability allows a larger segment of the population to opt for pacemaker implantations or treatments, boosting market growth. Moreover, increased healthcare spending and better insurance coverage contribute to expanded adoption rates, creating a favourable market landscape in these economies.
Competition from alternative therapies
Alternative treatments like medication, lifestyle changes, or other non-invasive cardiac interventions present alternatives to pacemaker implantation. For certain cardiac conditions, patients might opt for alternative therapies before considering a pacemaker due to concerns about surgery, device dependency, or cost. Moreover, advancements in non-invasive procedures and research into alternative treatments offer viable options, potentially reducing the immediate need for pacemakers.
The COVID-19 pandemic had a substantial impact on the external pacemaker market. Disruptions in healthcare services, elective procedures, and hospital visits led to deferred non-emergency treatments, including pacemaker implantations. Supply chain disruptions and the prioritisation of resources for pandemic-related care affected device availability. Patient reluctance to seek medical care and hospitalisations also contributed to reduced pacemaker procedures, resulting in a temporary decline in market growth.
The hospitals segment is expected to be the largest during the forecast period
During the forecast period, the hospitals segment is poised to dominate. Hospitals serve as primary centres for cardiac care, equipped with specialised infrastructure and skilled healthcare professionals capable of diagnosing and treating complex cardiac conditions requiring external pacemakers. Additionally, these facilities often witness a high influx of patients requiring immediate cardiac interventions, making them primary hubs for pacemaker implantations and management. The comprehensive healthcare services and specialised cardiology departments in hospitals solidify their position as the largest contributors to the external pacemaker market.
The heart block segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the heart block segment is anticipated to experience a lucrative growth rate. This is attributed to the increasing prevalence of heart block conditions, where the heart's electrical signals are delayed or obstructed. External pacemakers serve as essential temporary solutions for regulating the heart's rhythm in such cases, contributing to their heightened demand. Additionally, advancements in technology and a growing awareness of cardiac health are expected to drive the adoption of external pacemakers for heart block management, fueling the segment's rapid growth.
North America is positioned to secure the largest market share in the external pacemaker market owing to its advanced healthcare infrastructure, high prevalence of cardiac disorders, and substantial healthcare expenditure. Additionally, the presence of key market players and extensive research and development activities contribute to market dominance. Furthermore, increasing initiatives for technological advancements in cardiac care and a proactive approach to adopting innovative medical solutions reinforce North America's prominence in the external pacemaker market.
The Asia-Pacific region is poised for significant growth in the external pacemaker market due to the region's rising prevalence of cardiac disorders and an expanding geriatric population. Additionally, improving healthcare infrastructure, growing awareness about advanced medical treatments, and rising disposable incomes contribute to higher adoption rates of external pacemakers. Moreover, collaborations with international medical device manufacturers and supportive government initiatives further drive market expansion, indicating substantial growth prospects for the Asia-Pacific External Pacemaker market.
Key players in the market
Some of the key players in External Pacemaker Market include Abbott Laboratories, Biotronik, Boston Scientific Corporation, Cardiac Science Corporation, Cook Medical, Galix Biomedical Instrumentation, LivaNova Plc, Medtronic, Osypka Medical GmbH, Reka Health Pte Ltd., Schiller AG, Shree Pacetronix Ltd., Spacelabs Healthcare and ZOLL Medical Corporation.
In December 2023, Medtronic plc, a global leader in healthcare technology, announces that it has entered into a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals. This AI-driven partnership will further capitalize on the achievements already realized with the GI Genius™ intelligent endoscopy module, offering continued innovation and scalable healthcare advancements for patients and caregivers globally.
In November 2023, Boston Scientific Corporation announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only U.S. Food and Drug Administration-cleared Intracept® Intraosseous Nerve Ablation System, a therapy to treat vertebrogenic pain that is a form of chronic low back pain. The Intracept system, a basivertebral nerve ablation therapy, will be an addition to the Boston Scientific chronic pain portfolio that includes spinal cord stimulation, radiofrequency ablation and an interspinous spacer procedure.
In July 2023, Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms. With more than 80% of people who need a pacemaker requiring pacing in two chambers of the heart (both the right atrium and right ventricle), the approval significantly increases access to leadless pacing for millions of people across the U.S.